vs
Ginkgo Bioworks Holdings, Inc.（DNA）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.5倍（$50.3M vs $33.4M），READING INTERNATIONAL INC同比增速更快（-14.2% vs -23.8%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-47.7M），过去两年READING INTERNATIONAL INC的营收复合增速更高（5.6% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
DNA vs RDI — 直观对比
营收规模更大
RDI
是对方的1.5倍
$33.4M
营收增速更快
RDI
高出9.7%
-23.8%
自由现金流更多
RDI
多$51.8M
$-47.7M
两年增速更快
RDI
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $50.3M |
| 净利润 | — | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | -1.9% |
| 净利率 | — | -5.1% |
| 营收同比 | -23.8% | -14.2% |
| 净利润同比 | — | -14.5% |
| 每股收益（稀释后） | $-1.41 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARDI
| Q4 25 | $33.4M | $50.3M | ||
| Q3 25 | $38.8M | $52.2M | ||
| Q2 25 | $49.6M | $60.4M | ||
| Q1 25 | $48.3M | $40.2M | ||
| Q4 24 | $43.8M | $58.6M | ||
| Q3 24 | $89.0M | $60.1M | ||
| Q2 24 | $56.2M | $46.8M | ||
| Q1 24 | $37.9M | $45.1M |
净利润DNARDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $-80.8M | $-4.2M | ||
| Q2 25 | $-60.3M | $-2.7M | ||
| Q1 25 | $-91.0M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-56.4M | $-7.0M | ||
| Q2 24 | $-217.2M | $-12.8M | ||
| Q1 24 | $-165.9M | $-13.2M |
营业利润率DNARDI
| Q4 25 | -211.9% | -1.9% | ||
| Q3 25 | -231.8% | -0.6% | ||
| Q2 25 | -132.1% | 4.8% | ||
| Q1 25 | -184.1% | -17.2% | ||
| Q4 24 | -236.3% | 2.6% | ||
| Q3 24 | -62.0% | -0.6% | ||
| Q2 24 | -396.7% | -16.4% | ||
| Q1 24 | -469.1% | -16.7% |
净利率DNARDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | -207.9% | -8.0% | ||
| Q2 25 | -121.6% | -4.4% | ||
| Q1 25 | -188.2% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -63.3% | -11.7% | ||
| Q2 24 | -386.4% | -27.4% | ||
| Q1 24 | -437.3% | -29.4% |
每股收益（稀释后）DNARDI
| Q4 25 | $-1.41 | $-0.11 | ||
| Q3 25 | $-1.45 | $-0.18 | ||
| Q2 25 | $-1.10 | $-0.12 | ||
| Q1 25 | $-1.68 | $-0.21 | ||
| Q4 24 | $-1.91 | $-0.11 | ||
| Q3 24 | $-1.08 | $-0.31 | ||
| Q2 24 | $-4.23 | $-0.57 | ||
| Q1 24 | $-3.32 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $508.6M | $-18.2M |
| 总资产 | $1.1B | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNARDI
| Q4 25 | $422.6M | $10.5M | ||
| Q3 25 | $495.5M | $8.1M | ||
| Q2 25 | $559.4M | $9.1M | ||
| Q1 25 | $325.3M | $5.9M | ||
| Q4 24 | $561.6M | $12.4M | ||
| Q3 24 | $616.2M | $10.1M | ||
| Q2 24 | $730.4M | $9.3M | ||
| Q1 24 | $840.4M | $7.5M |
总债务DNARDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNARDI
| Q4 25 | $508.6M | $-18.2M | ||
| Q3 25 | $559.8M | $-12.1M | ||
| Q2 25 | $613.0M | $-7.7M | ||
| Q1 25 | $647.4M | $-8.1M | ||
| Q4 24 | $716.1M | $-4.4M | ||
| Q3 24 | $797.9M | $1.6M | ||
| Q2 24 | $833.1M | $6.5M | ||
| Q1 24 | $987.3M | $18.0M |
总资产DNARDI
| Q4 25 | $1.1B | $434.9M | ||
| Q3 25 | $1.2B | $435.2M | ||
| Q2 25 | $1.2B | $438.1M | ||
| Q1 25 | $1.3B | $441.0M | ||
| Q4 24 | $1.4B | $471.0M | ||
| Q3 24 | $1.5B | $495.7M | ||
| Q2 24 | $1.6B | $494.9M | ||
| Q1 24 | $1.6B | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $4.1M |
| 自由现金流率自由现金流/营收 | -142.8% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-2.9M |
8季度趋势，按日历期对齐
经营现金流DNARDI
| Q4 25 | $-47.7M | $4.3M | ||
| Q3 25 | $-31.6M | $295.0K | ||
| Q2 25 | $-40.3M | $1.6M | ||
| Q1 25 | $-51.5M | $-7.7M | ||
| Q4 24 | $-42.4M | $8.0M | ||
| Q3 24 | $-103.5M | $1.3M | ||
| Q2 24 | $-84.4M | $-10.4M | ||
| Q1 24 | $-89.3M | $-2.8M |
自由现金流DNARDI
| Q4 25 | $-47.7M | $4.1M | ||
| Q3 25 | — | $-246.0K | ||
| Q2 25 | $-40.3M | $1.2M | ||
| Q1 25 | $-59.1M | $-8.0M | ||
| Q4 24 | $-56.1M | $7.0M | ||
| Q3 24 | $-118.6M | $-1.1M | ||
| Q2 24 | $-111.4M | $-10.6M | ||
| Q1 24 | $-96.0M | $-4.7M |
自由现金流率DNARDI
| Q4 25 | -142.8% | 8.2% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | -81.2% | 1.9% | ||
| Q1 25 | -122.4% | -19.8% | ||
| Q4 24 | -128.0% | 12.0% | ||
| Q3 24 | -133.2% | -1.8% | ||
| Q2 24 | -198.2% | -22.7% | ||
| Q1 24 | -252.9% | -10.4% |
资本支出强度DNARDI
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 15.8% | 0.6% | ||
| Q4 24 | 31.3% | 1.7% | ||
| Q3 24 | 16.9% | 4.0% | ||
| Q2 24 | 48.1% | 0.5% | ||
| Q1 24 | 17.7% | 4.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
